Anixa BiosciencesANIX
ANIX
About: Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Employees: 5
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
72% more call options, than puts
Call options by funds: $122K | Put options by funds: $71K
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
18% more capital invested
Capital invested by funds: $13.6M [Q4 2024] → $16M (+$2.48M) [Q1 2025]
2% more funds holding
Funds holding: 57 [Q4 2024] → 58 (+1) [Q1 2025]
0.74% less ownership
Funds ownership: 18.15% [Q4 2024] → 17.41% (-0.74%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
218%
upside
Avg. target
$10
218%
upside
High target
$10
218%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 218%upside $10 | Buy Maintained | 10 Jun 2025 |
Financial journalist opinion
Based on 6 articles about ANIX published over the past 30 days
Positive
Zacks Investment Research
2 days ago
Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and CochLear Ltd. Unsponsored ADR (CHEOY) have performed compared to their sector so far this year.
Neutral
PRNewsWire
2 days ago
Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
SAN JOSE, Calif. , July 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025 covering key aspects of its ovarian cancer vaccine technology.
Positive
Zacks Investment Research
2 weeks ago
ANIXA BIOSCIENCES INC (ANIX) is a Great Momentum Stock: Should You Buy?
Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Negative
Zacks Investment Research
2 weeks ago
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.
Neutral
PRNewsWire
2 weeks ago
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Fourth cohort dose is three million CAR positive cells; thirty times higher than the first cohort dose SAN JOSE, Calif. , June 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the fourth dosage cohort in the ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer.
Neutral
PRNewsWire
3 weeks ago
Anixa Biosciences to Host an Investor Webcast on June 26, 2025
SAN JOSE, Calif. , June 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT.
Positive
Zacks Investment Research
1 month ago
What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now?
Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
PRNewsWire
1 month ago
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage
SAN JOSE, Calif. , June 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was featured on Fox News' "Fox & Friends.
Neutral
PRNewsWire
1 month ago
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025
SAN JOSE, Calif. , June 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy, will present an e-poster at the European Society for Medical Oncology ("ESMO") Gynaecological Cancers Congress 2025, to be held on June 19-21, 2025 in Vienna, Austria.
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy
Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Charts implemented using Lightweight Charts™